RxDoctor Payments Data

Shane McNamara Gazzo, PA

Physician Assistant · Newport, RINPI 1396425427

Payments from drug & device makers

$721in general payments, 2019–2025

Across 26 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$238
  • Pfizer$121
  • Paratek Pharmaceuticals, Inc.$109
  • Viiv Healthcare Company$104
  • AstraZeneca$74
  • Exact Sciences$25
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 75th percentile of 481 physician assistant providers in Rhode Island.

See all physician assistant providers in Rhode Island

Medicare billing

Part B allowed, 2024
$462
Medicare patients
15
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl30$36,001
OzempicSemaglutide36$34,752
Xtampza ErOxycodone Myristate20$32,097
TrulicityDulaglutide13$13,882
Combivent RespimatIpratropium/Albuterol Sulfate24$11,610
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,893
Oxycodone Hcl182$3,961
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen96$3,548
Metformin Hcl62$3,010
Albuterol Sulfate HfaAlbuterol Sulfate110$2,383
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,325
Gabapentin96$2,218
Atorvastatin Calcium193$1,999
Varenicline Tartrate13$1,895
Ventolin HfaAlbuterol Sulfate33$1,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$34,75236 claims
AbbVieSynthroid$238$53012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 physician assistant providers in Rhode Island.

Other physician assistant in Newport

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →